Normalized CT Dose Index of the CT Scanners Used in the National Lung Screening Trial
Overview
Authors
Affiliations
Objective: The National Lung Screening Trial includes 33 participating institutions that performed 75,133 lung cancer screening CT examinations for 26,724 subjects during 2002-2007. For trial quality assurance reasons, CT radiation dose measurement data were collected from all MDCT scanners used in the trial.
Materials And Methods: A total of 247 measurements on 96 MDCT scanners were collected using a standard CT dose index (CTDI) measurement protocol. The scan parameters used in the measurements (tube voltage, milliampere-seconds [mAs], and detector-channel configuration) were set according to trial protocol for average size subjects. The normalized weighted CT dose index (CTDI(w)) (computed as CTDI(w)/mAs) obtained from each trial-participating scanner was tabulated.
Results: We found a statistically significant difference in normalized CT dose index among CT scanner manufacturers, likely as a result of design differences, such as filtration, bow-tie design, and geometry. Our findings also indicated a statistically significant difference in normalized CT dose index among CT scanner models from the same manufacturer (e.g., GE Healthcare, Siemens Healthcare, and Philips Healthcare). We also found a statistically significant difference in normalized CT dose index among all models and all manufacturers; furthermore, we found a statistically significant difference in normalized CT dose index among CT scanners from all manufacturers when we compared scanners with four or eight data channels to those with 16, 32, or 64 channels, suggesting that more complex scanners have improved dose efficiency.
Conclusion: Average normalized CT dose index values varied by a factor of almost two for all scanners from all manufacturers. This study was focused on machine-specific normalized CT dose index; patient dose and image quality were not addressed.
The Impact of Radiation Dose on CT-Based Body Composition Analysis: A Large-Animal Study.
Salhofer L, Jost G, Meetschen M, van Landeghem D, Forsting M, Bos D J Cachexia Sarcopenia Muscle. 2025; 16(1):e13741.
PMID: 39980200 PMC: 11842463. DOI: 10.1002/jcsm.13741.
Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality.
Bonney A, Malouf R, Marchal C, Manners D, Fong K, Marshall H Cochrane Database Syst Rev. 2022; 8:CD013829.
PMID: 35921047 PMC: 9347663. DOI: 10.1002/14651858.CD013829.pub2.
LoDoPaB-CT, a benchmark dataset for low-dose computed tomography reconstruction.
Leuschner J, Schmidt M, Baguer D, Maass P Sci Data. 2021; 8(1):109.
PMID: 33863917 PMC: 8052416. DOI: 10.1038/s41597-021-00893-z.
Khoramian D, Sistani S, Firouzjah R Pol J Radiol. 2019; 84:e61-e67.
PMID: 31019596 PMC: 6479057. DOI: 10.5114/pjr.2019.82743.
Multifactorial Analysis of Mortality in Screening Detected Lung Cancer.
Digumarthy S, De Man R, Canellas R, Otrakji A, Wang G, Kalra M J Oncol. 2018; 2018:1296246.
PMID: 29861726 PMC: 5976935. DOI: 10.1155/2018/1296246.